Qrons
Develops 3D printable stem cell-synthetic hydrogel implants for treating traumatic brain injuries (TBI), targeting a $76B annual medical cost market.
- CEO / Founder
- Jonah Meer
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $1.18M
- Latest Round
- IPO
- Key Investors
- First Person Ltd.; Jonah Meer; Ido Merfeld; CubeSquare, LLC; Ariel Scientific Innovations (ASI) Ltd.
Technology & Products
Key Products
QS100™; QS200™
Technological Advantage
(1) Claimed: Customizable implants for specific brain injury geometries. (2) Verified: Exclusive worldwide license for 3D printable materials from Dartmouth (Patent US20190144569A1). Defensible via patents.
Differentiation
Value Proposition
Reduces long-term TBI complications by providing 3D printable, stem cell-integrated hydrogel implants that promote neuro-regeneration, targeting a $76B annual medical cost market.
How They Differentiate
Utilizes licensed 3D printing technology for mechanically interlocked molecules-based materials to create customizable, biocompatible implants for TBI.
Market & Competition
Target Customers
Hospitals, neurosurgical centers, and biotechnology research institutions treating traumatic brain injury (TBI) and neurodegenerative diseases.
Industry Verticals
Medical; Biotechnology
Competitors
Organovo; Aspect Biosystems; Precise Bio
Growth & Milestones
Growth Metrics
Raised $1.18M in total funding; Preclinical stage with lead candidates QS100 and QS200; Merged with First Person Ltd in February 2025 to expand into cognitive wellness and functional beverages.
Major Milestones
2016: Founded; 2019: Exclusive IP license with Dartmouth College; Development of QS100™ and QS200™ candidates
Notable Customers
Dartmouth College; Ariel University; Meir Hospital; First Person